Source: Eur Respir J 2014; 43: 872-883
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Warth Arne, Penzel Roland, Lindenmaier Heike, Brandt Regine, Stenzinger Albrecht, Herpel Esther, Goeppert Benjamin, Thomas Michael, Herth Felix J.F., Dienemann Hendrik, Schnabel Philipp A., Schirmacher Peter, Hoffmann Hans, Muley Thomas, Weichert Wilko. EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. Eur Respir J 2014; 43: 872-883

Member's Comments

No comment yet.

Related content which might interest you: Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort Source: Eur Respir J 2012; 40: 177-184 Year: 2012 EGFR, KRAS, HER2, BRAF and PI3KCA mutation status in metastatic cancer patients: Thoracic cytological specimens obtained in routine clinical practice Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 Correlation of p53, EGFR and HER2 expression in the diagnostic biopsies and the corresponding resected tumours in NSCLC Source: Eur Respir J 2003; 22: Suppl. 45, 198s Year: 2003 A detailed immunohistochemical analysis of PI3K/AKT/MTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 KRAS & TP53 mutations cause malignant mesothelioma Source: ERS Lung Science Conference 2017 Year: 2017 Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients Source: Eur Respir Rev 2014; 23: 390-392 Year: 2014 Asbestos-related lung cancers are rarely associated with ALK, ROS1 and RET rearrangements Source: Eur Respir J, 51 (3) 1702605; 10.1183/13993003.02605-2017 Year: 2018 Clinical features associated with epidermal growth factor receptor and K-RAS gene mutations in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 811s Year: 2006 Concordance of p53 and K-ras mutations in induced sputum and corresponding biopsies of patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 18s Year: 2001 Clinical relevance of p53 and K-ras gene mutations in bronchial margins in surgically treated nonsmall cell lung cancer (NSCLC) patients Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002 Mutation of TP53 and KRAS, and loss of p16ink4a and p14arf expression in lung cancers in relation to tobacco smoke Source: Eur Respir J 2005; 26: Suppl. 49, 93s Year: 2005 Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study Source: Eur Respir J, 51 (3) 1701467; 10.1183/13993003.01467-2017 Year: 2018 KRAS oncogene in lung cancer: focus on molecularly driven clinical trials Source: Eur Respir Rev 2015; 25: 71-76 Year: 2016 The correlation between p53 gene mutation and the expression of tumor drug resistance genes in lung cancer and its clinical significance Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer Source: Eur Respir J 2002; 19: 134-140 Year: 2002 Epigenetic inactivation of checkpoint kinase 2 gene in nonsmall cell lung cancer and its relationship with clinicopathological features Source: Annual Congress 2009 - Lung cancer biology Year: 2009 NKX2-1 impacts prognosis in early stage NSCLC not harboring TP53 mutations Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Arg72Pro P53 gene polymorphism is associated with P53 mutations in non-small cell lung cancer (NSCLC) patients Source: Eur Respir J 2004; 24: Suppl. 48, 78s Year: 2004 Characteristics and prognostic relevance of p53 gene mutations in Polish non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005